Other equities analysts have also recently issued reports about the stock. Goldman Sachs Group raised their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research note on Tuesday, November 19th. Canaccord Genuity raised their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a report on Wednesday, November 20th. Roth Capital raised their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Piper Jaffray Companies reiterated a buy rating and set a $104.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 16th. Finally, Oppenheimer lifted their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a report on Monday, November 25th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $71.38.
Shares of NASDAQ CRSP opened at $59.44 on Wednesday. The firm’s 50 day moving average price is $65.98 and its 200-day moving average price is $51.14. Crispr Therapeutics has a 52-week low of $28.95 and a 52-week high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. As a group, research analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter worth about $41,000. Aperio Group LLC purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter worth about $153,000. Swiss National Bank grew its holdings in shares of Crispr Therapeutics by 28.6% during the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock worth $2,289,000 after purchasing an additional 10,800 shares during the period. Wells Fargo & Company MN lifted its position in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Crispr Therapeutics during the 2nd quarter worth approximately $466,000. Institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Overbought
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.